Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos, María-Victoria, Masszi, Tamas, Grzasko, Norbert, Hansson, Markus, Sandhu, Irwindeep, Pour, Ludek, Viterbo, Luísa, Jackson, Sharon R., Stoppa, Anne-Marie, Gimsing, Peter, Hamadani, Mehdi, Borsaru, Gabriela, Berg, Deborah, Lin, Jianchang, Di Bacco, Alessandra, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622861/
https://www.ncbi.nlm.nih.gov/pubmed/28751562
http://dx.doi.org/10.3324/haematol.2017.170118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622861/
https://www.ncbi.nlm.nih.gov/pubmed/28751562
http://dx.doi.org/10.3324/haematol.2017.170118

Ejemplares similares